Literature DB >> 3359945

Synovial fluid and plasma kinetics of repeat dose sustained action tiaprofenic acid in patients with rheumatoid arthritis.

F E Nichol1, A Samanta, C M Rose.   

Abstract

Tiaprofenic acid is a potent non-steroidal anti-inflammatory drug which, in conventional tablet form, has been shown to be rapidly absorbed and eliminated from the plasma, while synovial fluid concentrations remain constant for at least 8 hours. Recently, a sustained action formulation of tiaprofenic acid has been developed to provide the patient with the convenience of a once daily dosage. The purpose of this study was to measure plasma and synovial fluid concentrations over a 24-hour period following repeated administration of the sustained action formulation, and thus determine the pharmacokinetic profile. Eight patients suffering from rheumatoid arthritis were included in this open study (of whom 3 were subsequently excluded from the analysis). All were hospital outpatients requiring aspiration of the knee joint. The patients received sustained action tiaprofenic acid in a dosage of 600 mg once daily for a period of 7 days. Plasma and synovial fluid samples were taken on the final treatment day at 0, 4, 8, 12, and 18 hours following administration of the last treatment dose. Areas under the concentration-time curves, maximum plasma and synovial fluid concentrations, times to maximum concentration, and apparent elimination half-lives are presented and the findings compared and discussed. The drug was found to be retained in both the plasma and synovial fluid over a 24-hour period. Synovial fluid concentrations exceeded plasma concentrations at 24 hours in 4 of the 5 patients who were analysed, while in the fifth patient the levels were very similar.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3359945     DOI: 10.2165/00003495-198800351-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

1.  Pharmacokinetics of the anti-inflammatory tiaprofenic acid in humans, mice, rats, rabbits, and dogs.

Authors:  J Pottier; D Berlin; J P Raynaud
Journal:  J Pharm Sci       Date:  1977-07       Impact factor: 3.534

2.  A comparison of a sustained release preparation of tiaprofenic acid with the conventional tablet formulation and a placebo in rheumatoid arthritis.

Authors:  W Essigman; J Lambert; P Sheldon; B J Sweetman; J Wojtulewski
Journal:  Int J Clin Pharmacol Res       Date:  1987

3.  Short-term efficacy and tolerance of tiaprofenic acid ('Surgam') in rheumatoid arthritis and osteoarthritis: multi-centre, placebo-controlled trials.

Authors:  M Thompson; T J Daymond; W K Essigman; E C Huskisson; J A Wojtulewski
Journal:  Curr Med Res Opin       Date:  1982       Impact factor: 2.580

  3 in total
  8 in total

Review 1.  Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Authors:  P Netter; B Bannwarth; M J Royer-Morrot
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

Review 2.  Symposium on therapeutic aspects of tiaprofenic acid.

Authors:  J P Famaey
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Dermacase. Contact photodermatitis.

Authors:  T Enta
Journal:  Can Fam Physician       Date:  1995-04       Impact factor: 3.275

4.  Dermacase. Acanthosis nigricans.

Authors:  T Enta
Journal:  Can Fam Physician       Date:  1995-01       Impact factor: 3.275

5.  Dermacase. Nevus araneus (spider telangiectasia).

Authors:  T Enta
Journal:  Can Fam Physician       Date:  1994-06       Impact factor: 3.275

Review 6.  Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

7.  Pharmacokinetics of lumiracoxib in plasma and synovial fluid.

Authors:  Graham Scott; Christiane Rordorf; Christine Reynolds; Jyoti Kalbag; Michael Looby; Slavica Milosavljev; Margaret Weaver; John P Huff; Dennis A Ruff
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases.

Authors:  G L Plosker; A J Wagstaff
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.